Still not profitable yet involved in multiple patent lawsuits, Yifang Bio claims that it is not involved in the research pipeline.
① Yifang Biotechnology and its controlling person are involved in a patent infringement lawsuit, being asked to pay 99 million yuan. Yifang Biotechnology's revenue for the first three quarters of 2024 is less than 20 million yuan, and it has not yet achieved profitability; ② Company personnel stated that the lawsuit targets some patents related to Yifang Biotechnology's intellectual property and does not involve the research pipeline.
After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?
① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.
Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.
①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.
TJ Darentang USD: Wang Lei replaces Zhang Mingrui as the chairman, the company's development global strategy "will not change" | Speed reading announcement
① Zhang Mingrui applied to resign as the chairman, director, and chairman of the global strategy committee of tj darentang usd due to work changes. ② Wang Lei, the general manager, took over as chairman, with company officials stating that the enterprise development strategy "will not change".
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
tj darentang plans to sell 13% of its stake in China and America Shire, pending antitrust review | Directly hitting the shareholder meeting.
At today's tj darentang shareholder meeting, the proposal to sell 13% equity of China-US Tianjin Shexi Pharmaceutical Co., Ltd. (referred to as China-US Shexi) to Heiliong was approved. Company chairman Zhang Mingrui said: "China-US Shexi is an excellent company, and the main reason for this equity sale is the expiration of the 40-year cooperation period." This equity sale still needs to be reviewed for anti-monopoly by the State Administration for Market Regulation on Heiliong's side.